Upcoming Events
Vaccitech KOL Webinar: The SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases
Protalix Biotherapeutics: KOL Event on Fabry Disease & PRX-102 (pegunigalsidase alfa)
Xilio Therapeutics Virtual Program Spotlight on XTX301: A Tumor-Activated IL-12
Lumos Pharma KOL Webinar Discussing Encouraging Interim Results from Two Phase 2 LUM-201 Trials for Pediatric Growth Hormone Deficiency
12th Annual LifeSci Partners Corporate Access Event
Sensei Biotherapeutics Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint
Vera Therapeutics KOL Event on IgA Nephropathy (IgAN) Featuring Jonathan Barratt, PhD, FRCP: Targeting the Source of Disease
IDEAYA Biosciences Investor R&D Day
Y-mAbs Therapeutics In-Person Research & Development Day
Vaccitech KOL Webinar: Status of Tolerogenic Immunotherapies for Celiac Disease and Other Autoimmune Diseases with a Focus on VTP-1000
Valneva In-Person Investor Day
Monthly State of the Biotech Markets: Sector News and Capital Markets Update, Hosted by LifeSci Partners
Calliditas Therapeutics Fireside Chat: The IgAN Treatment Landscape
Mendus KOL Event: Immunotherapy for Maintenance Treatment of Acute Myeloid Leukemia Patients in Remission
TScan Therapeutics: Multiplexed TCR-T Therapy: The Next Generation of Cell Therapy for Solid Tumors
Protected: Ideaya BioSciences Synthetic Lethality Investor Day
Antengene R&D Day: Treating Patients Beyond Borders
Theriva Biologics KOL Event on Advancing Unique Oncolytic Virus Therapeutics
OKYO Pharma KOL Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
Oncolytics Biotech KOL Webinar on Pancreatic Cancer and Interim Results from the Phase 1/2 GOBLET Study Being Presented at the SITC 37th Annual Meeting
Mereo BioPharma: R&D Update on Mereo’s Alvelestat Program for Alpha-1 Antitrypsin Deficiency Lung Disease
ALIGOS Therapeutics: Analyst & Investor Reception at AASLD
TME Pharma KOL Webinar: NOX-A12 Combination Therapies in First-Line Glioblastoma – The Key to the TME? Analysis of Maturing Data from the Ongoing GLORIA Trial
Vera Therapeutics KOL Event on IgA Nephropathy (IgAN) Featuring Jonathan Barratt, PhD, FRCP: Targeting the Source of Disease with Vera Therapeutics
Gritstone bio’s Approach to Infectious Diseases: Data Update on Self-amplifying mRNA (samRNA) Vaccines Against COVID-19
Olema Oncology: ENA 2022: OP-1250 Phase 1/2 Study Update
Sensei Biotherapeutics KOL Event on VISTA: A Suppressor of T-Cells
Cyclacel R&D Day: Program Update on Cyclacel’s Oral CDK2/9 and PLK1 Inhibitors in Solid Tumors and Lymphoma
Arrowhead Pharmaceuticals: Virtual Investor & Analyst Event
LifeSci Platform
Founded in 2009, by Andrew McDonald PhD and Michael Rice, LifeSci is a platform of strategic healthcare advisory services in the areas of Investor Relations, Communications, Venture Investing, Partnering & Analytics, Capital Market Services, Executive Search and On-Demand Talent.
Comprehensive investor relations development and customized corporate communications advisory.
Investment banking services including equity/debt issuance, corporate finance and M&A advisory (member FINRA/SIPC).
Executive recruitment services operating globally and exclusively in the healthcare sector.
Early-stage investing division that partners with emerging healthcare companies during pre-public institutional rounds.
A global commercial strategy and transactions consultancy empowering corporate and business development.
Provides On Demand C-Level leaders who are available to guide clients through every stage of growth or change management.
Global communications and marketing agency focused in life science and medical technology.
First Though connects you with life science subject matter experts through our team of dedicated healthcare professionals and scientists.